ScholarIQanswers from OpenAlex

Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial

PaperCitations, authors & open-access status

Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial have?

ScholarIQcitation count

Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial has 6 citations in the OpenAlex counts ScholarIQ stores.

When was Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial published?

ScholarIQyear

Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial has 2025 year in the ScholarIQ index.

What is the open-access status of Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial?

ScholarIQoa status

Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial has hybrid oa status in the ScholarIQ index.

What is the DOI of Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial?

ScholarIQdoi

The DOI for Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial is on the source record.

What is the PMID of Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial?

ScholarIQpmid

The PMID for Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial is on the source record.

What is the OpenAlex record for Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial?

ScholarIQopenalex

The OpenAlex for Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial